Verastem News

Express News | Verastem Oncology Announces Appointment of John Hayslip, M.d., to Chief Medical Officer

Moomoo 24/7Apr 18 16:05 ET

Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), Laboratory (LH) and Longboard Pharmaceuticals (LBPH)

TipRanksApr 16 06:00 ET

VS-6766 Drug Research 2024: Developed by Verastem Oncology, An RAF/MEK Clamp That Induces Inactive Complexes of MEK With ARAF, BRAF, and CRAF - Market Size, Forecast, and Emerging Insights 2019-2032

Yahoo FinanceApr 16 05:05 ET

Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Verastem (VSTM)

TipRanksApr 12 07:00 ET

Verastem Releases Updated Corporate Presentation for Investors

TipRanksApr 9 17:22 ET

Express News | Verastem Oncology Partner GenFleet Therapeutics Unveils Latest Research Findings Of GFH375 At AACR Annual Meeting

Moomoo 24/7Apr 9 07:16 ET

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to

BusinesswireApr 4 07:30 ET

Catalyst Watch: Tesla Deliveries, Disney Board Vote, DJT Drama and Fortinet Event

Seeking AlphaMar 28 15:00 ET

Verastem's Strategic Advancements and Financial Stability Underscore Buy Rating

TipRanksMar 27 03:15 ET

Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More

Seeking AlphaMar 24 08:01 ET

Express News | HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $17.5 Price Target

Moomoo 24/7Mar 19 06:38 ET

Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living With Low-Grade Serous Ovarian Cancer

Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their

BusinesswireMar 18 07:00 ET

Analysts' Top Healthcare Picks: Verastem (VSTM), Akebia Therapeutics (AKBA)

TipRanksMar 16 12:30 ET

Verastem Inc. at a Crossroads: Navigating the Perilous Terrain of Patent Ownership and IP Rights

TipRanksMar 16 02:02 ET

Express News | RBC Capital Reiterates Outperform on Verastem, Maintains $32 Price Target

Moomoo 24/7Mar 15 12:46 ET

Verastem Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/15/2024 191.31% RBC Capital → $32 Reiterates Outperform → Outperform 11/21/2023 145.79% BTIG → $27 Assu

BenzingaMar 15 12:45 ET

RBC Capital Sticks to Its Buy Rating for Verastem (VSTM)

TipRanksMar 15 06:46 ET

Recap: Verastem Q4 Earnings

Verastem (NASDAQ:VSTM) reported its Q4 earnings results on Thursday, March 14, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsVerastem missed estimated earnings by

BenzingaMar 14 17:55 ET

Express News | Verastem Q4 2023 Adj EPS $(1.10) Misses $(0.62) Estimate

Moomoo 24/7Mar 14 16:17 ET

Verastem 4Q Loss $27.4M >VSTM

Verastem 4Q Loss $27.4M >VSTM

Dow JonesMar 14 16:05 ET